Fig. 1 · Structure

Documents & Downloads

Telotristat ethyl (LX 1606 ethyl)

Cat. No. A11785 CAS 1033805-22-9

Serotonin synthesis inhibitor

LX 1606 is an orally bioavailable, small-molecule, tryptophan hydroxylase (TPH) inhibitor with potential antiserotonergic activity.

In Stock

Free Aliquoting for Your Order

Tell us your preferred amount per vial. We’ll confirm the options.

Telotristat ethyl (LX 1606 ethyl) Research Summary

This section summarizes 1 in vitro study and 3 in vivo studies of Telotristat ethyl (LX 1606 ethyl) from 3 published references.

Telotristat ethyl (LX 1606 ethyl) In Vitro Studies

Telotristat ethyl was evaluated using human recombinant TPH1 enzyme in a reaction mixture. The reported IC50 for LX1606 was 1.44 × 10–06 M. [1]

Literature-reported observations and conditions; not Adooq-tested protocols or general treatment recommendations.

Activity in a human recombinant enzyme assay

Biochemical assay · in_vitro: human recombinant TPH1 enzyme [1]

Telotristat ethyl was tested in a reaction mixture containing human recombinant TPH1 enzyme. The reported IC50 for LX1606 was 1.44 × 10–06 M.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
relative enzymatic activity of TPH1IC50 1.44 × 10–06 M[1]

Literature-Reported Treatment Conditions

Treatment concentration
3 nM to 10 μM
Exposure duration
at room temperature (RT) for 10 min
Method
reaction mixture
Reported limits
Not stated in the sentences used: vehicle.
Methods and source locations

Compound reported in the paper: Telotristat ethyl; Compound label in the paper: LX1606

Literature evidence for the named compound in the stated model; no Adooq product-use or lot-performance claim.

Results > Potency and Selectivity Profiling of TPT-004 in AAAH Assays (S6, S8, S10); Materials and Methods > TPH1 Activity Assay (S141, S142, S143, S145)

relative enzymatic activity of TPH1: relative enzymatic activity of TPH1; comparator: positive control samples (complete reaction mix, no inhibitor test compound) — Results > Potency and Selectivity Profiling of TPT-004 in AAAH Assays (S8, S10)

Telotristat ethyl (LX 1606 ethyl) In Vivo Studies

In peritoneal dissemination xenografts, Telotristat ethyl alone slightly increased median survival compared to controls, without statistical significance. In iCCA xenografts, Telotristat ethyl reduced net tumour growth compared to controls. In male mice exposed to CDCA enema, Telotristat ethyl significantly reduced gastrointestinal transit distance compared to the CDCA group. [2,3]

Survival in peritoneal dissemination xenografts

Animal study · peritoneal dissemination xenografts using NOD/SCID mice; n = 6–7 per group [2]

NOD/SCID mice bearing peritoneal dissemination xenografts received Telotristat ethyl at 100 mg/kg. Median survival was 52 days with treatment alone versus 47 days in controls; the increase was not statistically significant.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
median animal survivalmedian animal survival 52 days[2]

Conditions shared by the study groups

Treatment course
Ten days post‐tumour cell injection; 5 days per week; for 2 weeks
Study groups and reported outcomes
Group / doseComparatorObserved resultReference
Telotristat ethyl 100 mg/kgphosphate‐buffered saline (control)Treatment with TE alone resulted in a slight increase in animal survival (52 days); not statistically significant compared to controls; median animal survival in controls was 47 days[2]
Telotristat ethyl 100 mg/kg
Model: peritoneal dissemination xenografts using NOD/SCID mice; n = 6–7 per group
Reported limits: Not stated in the sentences used: route, vehicle.
Methods and source locations

Compound reported in the paper: Telotristat ethyl

Literature evidence for the named compound in the stated model; no Adooq product-use or lot-performance claim.

MATERIALS AND METHODS > Animal studies > Animal survival study (S20, S21, S22); RESULTS > Animal survival benefits of telotristat ethyl and cytotoxic agents (S57, S58)

median animal survival: median animal survival; comparator: phosphate‐buffered saline (control) — RESULTS > Animal survival benefits of telotristat ethyl and cytotoxic agents (S57, S58)

Telotristat ethyl 100 mg/kg · MATERIALS AND METHODS > Animal studies > Animal survival study (S22); RESULTS > Animal survival benefits of telotristat ethyl and cytotoxic agents (S57, S58)

Gastrointestinal transit after CDCA exposure

Animal study · Male C57BL/6 mice; 5 mice [3]

Male mice received Telotristat ethyl at 200 mg/kg by intraperitoneal injection after CDCA enema exposure. Compared to the CDCA group, gastrointestinal transit distance 30 minutes after carmine administration was significantly reduced in the Telotristat ethyl group.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
GI transit distance 30 minutes after carmine administrationReported result Compared to the CDCA group, GI transit distance 30 minutes after carmine administration was significantly reduced in the alosetron, GR113808, and LX1606 groups[3]

Conditions shared by the study groups

Route
intraperitoneal injection
Treatment course
After 7 days of CDCA (20 mg/kg) enema; for 7 consecutive days
Study groups and reported outcomes
Group / doseComparatorObserved resultReference
Telotristat ethyl 200 mg/kgThe Control group and the CDCA (20 mg/kg) group received PBS via intraperitoneal injection.Compared to the CDCA group, GI transit distance 30 minutes after carmine administration was significantly reduced in the alosetron, GR113808, and LX1606 groups[3]
Telotristat ethyl 200 mg/kg
Model: Male C57BL/6 mice; 5 mice
Reported limits: Not stated in the sentences used: vehicle.
Methods and source locations

Compound reported in the paper: Telotristat ethyl; Compound label in the paper: LX1606

Literature evidence for the named compound in the stated model; no Adooq product-use or lot-performance claim.

Methods > CDCA treatment in mice (S32); Methods > Carmine red assay for intestinal motility (S45); Methods > Tph1 inhibitor and 5-HTRs antagonists (S52, S53, S54, S55); Results > Inhibition of 5-HT synthesis or blocking 5-HT receptors reversed CDCA-induced enhancement of intestinal motility (S111)

GI transit distance 30 minutes after carmine administration: GI transit distance 30 minutes after carmine administration; comparator: The Control group and the CDCA (20 mg/kg) group received PBS via intraperitoneal injection. — Results > Inhibition of 5-HT synthesis or blocking 5-HT receptors reversed CDCA-induced enhancement of intestinal motility (S111)

Telotristat ethyl 200 mg/kg · Methods > Tph1 inhibitor and 5-HTRs antagonists (S52, S53); Results > Inhibition of 5-HT synthesis or blocking 5-HT receptors reversed CDCA-induced enhancement of intestinal motility (S111)

Tumour growth in iCCA xenografts

Animal study · iCCA CC‐LP‐1 xenografts; NOD/SCID mice; at least five mice per group [2]

NOD/SCID mice bearing iCCA xenografts received Telotristat ethyl at 100 mg/kg. Net tumour growth was reduced to 93 mm3 compared to 199 mm3 in controls.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Net tumour growthNet tumour growth 93 mm3[2]

Conditions shared by the study groups

Treatment course
Ten days after tumour cell injection; 5 days per week; for 2 weeks
Study groups and reported outcomes
Group / doseComparatorObserved resultReference
Telotristat ethyl 100 mg/kgPBS (control)Net tumour growth, compared to controls (199 mm3), was reduced to 93 mm3 (TE)[2]
Telotristat ethyl 100 mg/kg
Model: iCCA CC‐LP‐1 xenografts; NOD/SCID mice; at least five mice per group
Reported limits: Not stated in the sentences used: route, vehicle.
Methods and source locations

Compound reported in the paper: Telotristat ethyl

Literature evidence for the named compound in the stated model; no Adooq product-use or lot-performance claim.

MATERIALS AND METHODS > Animal studies > Tumour growth inhibition studies in CDX models (S26, S28, S29); RESULTS > Tumour growth inhibition by telotristat ethyl and cytotoxic agents in cell‐derived xenografts (S64, S66); FIGURE 2 legend (S125, S126)

Net tumour growth: Net tumour growth; comparator: PBS (control) — RESULTS > Tumour growth inhibition by telotristat ethyl and cytotoxic agents in cell‐derived xenografts (S66)

Telotristat ethyl 100 mg/kg · MATERIALS AND METHODS > Animal studies > Tumour growth inhibition studies in CDX models (S29); RESULTS > Tumour growth inhibition by telotristat ethyl and cytotoxic agents in cell‐derived xenografts (S66); FIGURE 2 legend (S126)

Specifications

Manufacturer Adooq Bioscience
Actions Inhibitor
CAS Number 1033805-22-9
Applications Serotonin synthesis inhibitor
Formula C27H26ClF3N6O3
Molecular Weight 575
Synonyms LX1606; LX 1606 ethyl
SMILES
CCOC(=O)[C@H](CC1=CC=C(C=C1)C2=CC(=NC(=N2)N)O[C@H](C3=C(C=C(C=C3)Cl)N4C=CC(=N4)C)C(F)(F)F)N

Storage & Solubility

In Vitro Solubility

Reported Solubility

No reported solubility data are available for this product.

Preparing Stock Solutions

Stock preparation is unavailable for this product molecular weight.

Calculated stock concentrations do not establish solvent solubility. Refer to the reported solubility data for experimental guidance.

Storage

Store powder at -20°C, keep desiccated.
In powder form, the chemical is stable for 36 months.
In solution, store at -20°C and use within 1 month to prevent loss of potency. Aliquot to avoid multiple freeze/thaw cycles.

Telotristat ethyl (LX 1606 ethyl) Research References

  1. [1] Wesolowski R, Schütz A, Lisurek M, et al. Selectivity and Safety Characterization of a Xanthine-Imidazothiazole Lead Structure: a Novel Tryptophan Hydroxylase Inhibitor of Peripheral Serotonin Synthesis. ACS Pharmacol Transl Sci (2025). PMID: 40534674 DOI: 10.1021/acsptsci.5c00043 Source material
  2. [2] Awasthi N, Darman L, Schwarz MA, et al. Telotristat ethyl, a tryptophan hydroxylase inhibitor, enhances antitumor efficacy of standard chemotherapy in preclinical cholangiocarcinoma models. J Cell Mol Med (2024). PMID: 39223878 DOI: 10.1111/jcmm.18585 Source material
  3. [3] Shan Z, He C, Yang Q, et al. Chenodeoxycholic acid activates the TGR5/TRPA1-5-HT pathway to regulate intestinal motility in breastfed infants and mouse models. Transl Pediatr (2025). PMID: 40688229 DOI: 10.21037/tp-2025-100 Source material

Added to your cart

View Cart Checkout
Loading...